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Abstract Mitochondrial adenine nucleotide translocase 1
(ANT1), but not ANT2, can dominantly induce apoptosis
[Bauer et al. (1999) J. Cell Biol. 439, 258^262]. Nothing is known,
however, about the apoptotic activity of ANT3. We have trans-
fected HeLa cells with the three human ANT isoforms to com-
pare their potential as inducers of apoptosis. Transient overex-
pression of ANT3 resulted, like ANT1, in apoptosis as shown by
an increase in the sub-G1 fraction, annexin V staining, low
v8m, and activation of caspases 9 and 3. Moreover, the apo-
ptosis produced by ANT3 was inhibited by bongkrekic acid and
by cyclosporin A. The pro-apoptotic activities of the ANT1 and
ANT3 isoforms contrast with the lack of apoptotic activity of
ANT2. This ¢nding may help to identify the speci¢c factors
associated with the pro-apoptotic activities of ANT isoforms.
5 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Adenine nucleotide translocase (ANT) plays a role in the
exchange of ATP for ADP through the inner mitochondrial
membrane, thus supplying the cytoplasm with newly synthe-
sized ATP in oxidative phosphorylation. ANT is a nuclear-
encoded gene with an Mr of 32 000 and is thought to function
as a homodimer [1,2]. It is an integral membrane protein
comprising six transmembrane segments with both the N-ter-
minal and C-terminal ends facing the intermembrane space
[3^5]. Its crystallographic 2.2 A= structure in complex with
carboxyatractyloside has recently been reported [6]. During
the transport of ADP and ATP it is assumed that ANT
changes from the c-conformation to the m-conformation in
which the substrate binding site is oriented towards the cyto-
plasm or the matrix respectively [7]. Atractyloside and carboxy-
atractyloside are speci¢c inhibitors of ANT that act by ¢xing
the c-conformation, whereas bongkrekic acid (BKA) inhibits
ANT by ¢xing the m-conformation [7]. In humans there are
three closely related isoforms that are expressed in a tissue-
speci¢c manner. ANT1 is mainly expressed in the heart, skel-
etal muscle and brain, ANT2 is expressed in liver and in cells
capable of proliferation and ANT3 is ubiquitously expressed
[8^10]. Even though the amino acid sequence identity among
these isoforms is very high (70^80%) it is thought that some
functional di¡erences might exist to explain their expression
patterns. In support of this, there is some evidence that ANT2
could favor the mitochondrial uptake of cytosolic ATP in
situations where oxidative phosphorylation is inhibited [9].
Apart from its role in nucleotide translocation, ANT is a
core component of the so-called mitochondrial permeability
transition pore (MPTP). This is a protein complex found in
the mitochondrial contact sites that, when it is open, acts as a
non-speci¢c channel, allowing the free passage of molecules
under 1500 Da through the inner mitochondrial membrane
[11,12]. As a consequence, mitochondria lose their mitochon-
drial membrane potential (v8m) and swell [13,14]. Several
pharmacological and physiological regulators of MPTP exist,
among them calcium has a signi¢cant role [11,15,16]. Inhib-
itors of ANT a¡ect MPTP; thus, atractyloside activates
MPTP whereas BKA inhibits it [17]. The involvement of
MPTP in apoptosis has been reported by a number of groups
[18^20]. In a search for pro-apoptotic proteins, Bauer et al.
[21] identi¢ed ANT1 as a protein that can dominantly induce
apoptosis. The overexpression of ANT1 produced a rapid cell
death, with a concomitant decrease in v8m and an increase in
nucleosomal DNA degradation. Cell death was sensitive to a
caspase inhibitor and to inhibitors of MPTP, indicating alto-
gether that apoptosis took place and that MPTP was involved
[21]. Interestingly, the overexpression of ANT2 had no e¡ect
on cell death [21]. This contrasts with the ability of both iso-
forms to interact with proteins of the Bcl2 family, such as Bax
and Bcl2 [22,23]. The isoform speci¢city of the apoptotic ac-
tivity of ANT prompted us to investigate the activity of the
third ANT isoform (ANT3), whose physiological role has not
been studied to date. We observed that overexpression of
ANT3 in HeLa cells induces apoptosis mainly through the
mitochondrial pathway. This result will help in identifying
the determinants of the pro-apoptotic activity of ANT1 and
ANT3 that are absent in ANT2.
2. Materials and methods
2.1. Cell culture and transfection
HeLa cells (ATCC-CC-1) were maintained in Dulbecco’s modi¢ed
Eagle’s medium (DMEM) containing 100 U/ml penicillin/streptomy-
cin and supplemented with 10% fetal bovine serum (FBS) (Gibco
BRL). The cells were incubated at 37‡C in a 95% air, 5% CO2 atmo-
sphere. Cells were transfected by standard calcium phosphate precip-
itation. A co-transfected green £uorescent protein (GFP) expression
plasmid was used to assess the transfection e⁄ciency (around 80% in
all cases). When indicated, cells were incubated with a combination of
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cyclosporin A (CsA) (5 WM, Sigma) plus tri£uoropyrasine (TFP)
(2 WM, Sigma) or with BKA (50 WM, Sigma).
2.2. Plasmid constructs and cDNAs
Reverse transcription polymerase chain reaction was used to obtain
the cDNAs of the human ANT isoforms from HeLa cell RNA.
cDNAs encoding full-length ANT isoforms were cloned into the
pcDNA3.1-Zeo(+) vector (Invitrogen). The plasmid pGFP-N3 (Clon-
tech) was used to assess the transfection e⁄ciency by co-transfection.
2.3. Cell fractionation
HeLa cells were collected, washed with phosphate-bu¡ered saline
(PBS) and centrifuged at 500Ug for 2 min. The pellets were re-sus-
pended in 1 ml of homogenization bu¡er (250 mM sucrose, 1 mM
EGTA, 10 mM HEPES pH 7.4, 1 mM phenylmethylsulfonyl £uoride,
Complete-Mini Protease Inhibitor cocktail tablets (Roche)). Cells
were disrupted by 50 strokes in a glass homogenizer and then centri-
fuged at 1500Ug for 10 min at 4‡C to remove unbroken cells, plasma
membranes and nuclei. Supernatants were further centrifuged at
10 000Ug for 10 min and the resultant pellet corresponded to the
mitochondria-enriched fraction, and the supernatants were used as
crude cytosolic extracts. Protein levels were quanti¢ed using the Brad-
ford method (Bio-Rad).
2.4. Immunoblotting
Homogenates and mitochondrial extracts of transiently transfected
cells were prepared as described above. The samples were separated
by sodium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) on 12.8% acrylamide gels and transferred to a polyvinylidene
di£uoride membrane (Immobilon-P, Millipore). Membranes were
blocked overnight with 5% skimmed milk containing 0.5% Tween
Fig. 1. Overexpression of ANT1, ANT2 and ANT3 proteins in
HeLa cells 24 h after transfection. Proteins from cell homogenates
(35 Wg) (A) and puri¢ed mitochondrial fractions (35 Wg) (B) of
transfected cells were separated by SDS^PAGE, transferred to mem-
branes and analyzed for the expression of ANT, L-actin and VDAC
with speci¢c antibodies as indicated.
Fig. 2. Nucleosomal DNA degradation produced by overexpression of ANT1, ANT2 and ANT3 proteins. Twenty-four hours after transfection,
HeLa cells overexpressing ANT1, ANT2 and ANT3 proteins, untransfected cells (control) and cells transfected with the empty vector (vector)
were stained with PI and analyzed for sub-G1 DNA fraction by £ow cytometry. As a positive control, HeLa cells were treated with 0.1 WM
staurosporine (STP) for 16 h, and analyzed in the same way. The percentage of the sub-G1 fraction is indicated.
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and then incubated with di¡erent primary antibodies: ANT (1:100;
Q-18, Santa Cruz Biotechnology), L-actin (1:10 000; AC-15, Sigma)
or VDAC (1:1000; 31HL, Calbiochem Biosciences). For caspase 9
analysis, whole homogenate membranes were stripped and reprobed
with a polyclonal antibody against cleaved caspase 9 (Asp 315)
(1:1000, Cell Signaling). Antibody binding was detected with horse-
radish peroxidase-coupled anti-mouse, anti-rabbit or anti-goat (Santa
Cruz) secondary antibodies and an enhanced chemiluminescence
(ECL) detection kit (Amersham Biosciences).
2.5. Fluorometric determination of caspase 3 activity
Caspase 3 activity was determined by £uorometry. Cytosolic ex-
tracts were incubated with the £uorogenic substrate Ac-DEVD-
AMC (Promega).
2.6. Assessment of apoptosis by £ow cytometry
The viability of transiently transfected cells was analyzed 24 h after
transfection. Apoptotic cells were detected by £ow cytometry after
staining with £uorescein isothiocyanate-conjugated annexin V and
propidium iodide (PI) using a commercially available kit (Annexin-
V-FLUOS Kit, Roche Molecular Biochemicals). Cells were considered
apoptotic when they were annexin V-positive and PI-negative. Stain-
ing of cells by PI was used as an indicator of the loss of plasma
membrane integrity. PI staining was also used to measure nucleoso-
Fig. 3. Apoptosis induced by overexpression of ANT1, ANT2 and ANT3 proteins. A: Twenty-four hours after transfection, HeLa cells overex-
pressing ANT proteins and cells transfected with the empty vector (vector) were analyzed for apoptosis by annexin V and PI staining by £ow
cytometry. B: Cells transfected with ANT3 plasmid were treated with BKA (50 WM) and with CsA (5 WM) plus TFP (2 WM) during the whole
procedure. Apoptosis was measured as in A. The percentage of annexin V-positive, PI-negative cells is indicated.
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mal DNA degradation. Flow cytometry was carried out using an
EPICS XL MCL (Beckman) cytometer.
2.7. Mitochondrial membrane potential
v8m was measured by £ow cytometry using hexamethylindodicar-
bocyanine iodide (DiIC1(5)) (Molecular Probes). Transiently trans-
fected cells were loaded with 40 nM DiIC1(5) for 20 min in DMEM
without FBS. At the end of the incubation period the cells were
washed twice in PBS, re-suspended in a total volume of 0.5 ml with
PBS and the v8m was analyzed by £ow cytometry in a Coulter EP-
ICS-XL-MCL (Beckman) cytometer.
3. Results
HeLa cells were transfected with the expression vectors con-
taining the coding sequences for human ANT1, ANT2 and
ANT3, resulting in the overexpression of these proteins (Fig.
1) detected by means of a non-isoform-speci¢c antibody
against ANT. The mitochondria of transfected cells showed
a marked increase in the amount of ANT (Fig. 1B), compared
to the control, mock-transfected cells, indicating that ANT
was properly directed to the mitochondria. Apoptosis results
in the degradation of nucleosomal DNA that can be quanti-
¢ed by £ow cytometry by analyzing the sub-G1 fraction of
DNA content. The overexpression of ANT1 and ANT3, 24 h
after transfection, produced an important increase in the sub-
G1 fraction (Fig. 2), indicating that extensive DNA degrada-
tion occurred. In contrast, the empty vector or ANT2 over-
expression did not generate this e¡ect (Fig. 2). As a positive
control, staurosporine treatment (0.1 WM, 16 h) resulted in
extensive DNA degradation as indicated by a marked increase
in the sub-G1 fraction (Fig. 2). Cells were analyzed for apo-
ptosis by staining of annexin V (Fig. 3). Whereas the trans-
fection of empty vector or the overexpression of ANT2
showed only slight staining for annexin V, the overexpression
of ANT1 and ANT3 resulted in massive cell death with a high
percentage of annexin V-positive cells (Fig. 3A). In order to
determine whether MPTP is involved in the cellular death
produced by ANT3 overexpression, we made use of two
known MPTP inhibitors, BKA and CsA used in combination
with TFP [24]. We observed that the pro-apoptotic e¡ect of
ANT3 was e¡ectively inhibited by these compounds (Fig. 3B).
To assess mitochondrial involvement in this apoptotic pro-
cess, v8m was measured. The empty vector or the overexpres-
sion of ANT2 had no e¡ect, resulting in an almost homoge-
neous population with normal v8m (Fig. 4). In contrast,
following the overexpression of ANT1 or ANT3 the cell pop-
ulation became biphasic: one half of the cells showed normal
v8m whereas the other half had very low v8m (Fig. 4). Fi-
nally, we measured caspase 9 and caspase 3 activities, nor-
mally used as indicators of the involvement of the intrinsic
or mitochondrial pathway of apoptosis. Caspase 9 activity
was determined by measuring the amount of the cleaved, ac-
tive caspase 9 by Western blot (Fig. 5A). The overexpression
of ANT1 and ANT3 resulted in the activation of caspase 9
whereas ANT2 overexpression had no e¡ect. In line with the
activation of caspase 9, caspase 3 was also speci¢cally induced
by ANT3 overexpression (Fig. 5B).
4. Discussion
We have demonstrated that the overexpression of ANT3
results in cell death; transfected cells have a high sub-G1
fraction, are annexin V-positive, have decreased v8m and in-
Fig. 4. E¡ects of ANT isoform overexpression on mitochondrial
membrane potential (v8m). Twenty-four hours after transfection,
HeLa cells overexpressing ANT isoforms and cells transfected with
the empty vector (vector) were incubated with the potential-sensitive
probe DiIC1(5) and analyzed by £ow cytometry. The percentage of
cells with low v8m is indicated.
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creased caspase 9 and 3 activities. All these results are con-
sistent with the induction of apoptosis as described previously
for ANT1 [21] and con¢rmed in our own experiments. Our
results also con¢rm the lack of e¡ect of the overexpression of
ANT2 in spite of its high amino acid identity with ANT1 and
ANT3, demonstrating that the e¡ects of ANT1 and ANT3 are
not due to an artifact of overexpression. The di¡erent ca-
pacity for producing apoptosis of ANT isoforms can be re-
lated to the ¢nding that ANT1 and ANT2 have distinct mi-
tochondrial localizations and di¡erent abilities to interact with
cyclophilin D [25]. In fact, there is evidence that the pro-ap-
optotic e¡ect of ANT1 is dependent upon MPTP activity,
since it is inhibited by the co-transfection of cyclophilin D
or by treatment of cells with BKA [21], a known inhibitor
of MPTP [17]. Similarly, we have shown that the pro-apopto-
tic e¡ect of ANT3 overexpression can be inhibited by BKA
and by CsA+TFP, indicating that, most likely, both ANT1
and ANT3 produce apoptosis through the same mechanism.
It is interesting to note that in cultured cells the major ANT
isoform expressed is ANT2, with very low, if any, levels of
ANT1 or ANT3 ([8], and data not shown). This may suggest
that ANT isoforms can induce apoptosis when expressed in
the wrong place or at the wrong time. This assumption could
explain why, despite its strong pro-apoptotic e¡ect in HeLa
cells, ANT1 is the major isoform expressed in skeletal muscle,
heart or brain [8,9] where it does not induce apoptosis and has
an important bioenergetic role. Interestingly, Bauer et al. [21]
reported that overexpression of ANT1 in yeast did not induce
cell death, indicating that it is not ANT1 per se that has the
ability to directly disturb the cell, but an interaction between
ANT1 and another protein that must be responsible for in-
ducing apoptosis. This putative protein probably inhibits
MPTP and apoptosis; thus, the overexpression of ANT1
would displace this protein from being attached to the
MPTP or other relevant complexes, in this way opening the
pore and inducing apoptosis [21]. A similar mechanism could
explain the e¡ects of ANT3. Of course, the interaction has to
be isoform-speci¢c, since ANT2 has no e¡ect at all on apo-
ptosis. ANT is a protein capable of multiple protein^protein
interactions. It interacts with other MPTP constituents, like
cyclophilin D and VDAC [11], and can also interact with
members of the Bcl2 family of proteins like Bax and Bcl2
[22,23]. In addition, ANT can bind the IUBK/NF-UB complex,
the inactive pool of NF-UB transcription factor, through its
interaction with IUBK [26]. This may represent another puta-
tive mechanism involved that may require further attention
because of the important role of NF-UB in apoptosis. Some
of these interactions with other proteins have been demon-
strated to be totally or partially isoform-speci¢c. Thus, it
seems that cyclophilin D has more a⁄nity for ANT1 than
for ANT2 [25], suggesting perhaps a major involvement of
ANT1 in the MPTP activity. It has also been reported that
ANT1 and ANT3 but not ANT2 bind ARL2 (ADP-ribosyla-
tion factor-like 2) and BART (binder of ARL2, with un-
known function) [27]. Direct involvement of ARL2-BART
in apoptosis induced by ANT has yet to be demonstrated,
but it is interesting to note that commonly used cell lines,
susceptible to the induction of apoptosis by overexpression
of ANT1 or ANT3, have almost undetectable levels of
BART-ARL2 proteins [27]. Our ¢nding that overexpression
of ANT3, like that of ANT1, induces apoptosis should be an
important aid in the search for the putative ANT^protein
interactions responsible for the induction of apoptosis.
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